Suglat
(Ipragliflozin)PreclinicalSmall molecule
AstellasIpragliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, which lowers blood sugar levels.[1] Suglat is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Suglat is one of 50 small molecule programs targeting Diabetes Mellitus. It is currently in Preclinical.
1
Indications
26
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
111 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Estrace
Novo NordiskApproved
Actigall
AbbVieApproved
Rifadin
SanofiApproved
Intropin
PfizerApproved
Neoral
NovartisApproved
Avelox
BayerApproved
Brilinta
AstraZenecaApproved
Adipex-P
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Synthroid
IInstitut Jerome Lejeune
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus11 trials
Show 8 more trials
Type 2 Diabetic Patients5 trials
Type 2 Diabetes3 trials
Safety and Efficacy2 trials
4 more indications
Clinical Efficacy and Safety1 trial
Non-Alcoholic Fatty Liver Disease1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ipragliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [4]